Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis
出版年份 2023 全文链接
标题
Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis
作者
关键词
-
出版物
CANCER
Volume 129, Issue 13, Pages 1969-1985
出版商
Wiley
发表日期
2023-03-30
DOI
10.1002/cncr.34755
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-small-cell Lung Cancer
- (2022) Peng Zhang et al. ANNALS OF THORACIC SURGERY
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2022) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study
- (2022) Hengyu Zhai et al. Cancer Management and Research
- Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers
- (2022) Joe Y. Chang et al. JAMA Oncology
- 84P SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: A randomized, double-blind, multicenter, phase Ib/III trial
- (2022) Y-L. Wu et al. ANNALS OF ONCOLOGY
- Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
- (2022) Fan Zhang et al. Journal of Thoracic Oncology
- Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer
- (2022) Junqi Wu et al. LUNG CANCER
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung cancer
- (2022) Xinlei Hou et al. Oncology Letters
- Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
- (2022) Yuanshan Yao et al. Frontiers in Surgery
- Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.
- (2022) Fuming Qiu et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
- (2022) Samuel Rosner et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
- (2022) Mariano Provencio et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Resection after Neoadjuvant Durvalumab and Radiation is Feasible and Safe in Non-Small Cell Lung Cancer: Results from a Randomized Trial
- (2022) Benjamin Lee et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
- (2022) Yang Gao et al. Frontiers in Oncology
- 950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial
- (2022) I. Bahce et al. ANNALS OF ONCOLOGY
- 942P Camrelizumab combined with albumin paclitaxel and platinum in perioperative treatment of resectable squamous cell lung cancer: A single-arm, open-label, phase II clinical trial
- (2022) Y. Zhang et al. ANNALS OF ONCOLOGY
- EP02.04-010 Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study
- (2022) x. cheng et al. Journal of Thoracic Oncology
- PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
- (2022) M. Provencio et al. Journal of Thoracic Oncology
- Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer
- (2022) Tianyu Ma et al. LUNG CANCER
- Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience
- (2021) Florian Eichhorn et al. LUNG CANCER
- Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: A retrospective study.
- (2021) Tianxiang Chen et al. ANNALS OF THORACIC SURGERY
- Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non–small cell lung cancer
- (2021) Betty C. Tong et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- FP03.02 Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- (2021) M.H. Hong et al. Journal of Thoracic Oncology
- PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
- (2021) J. Lee et al. Journal of Thoracic Oncology
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
- (2021) M. Wislez et al. ANNALS OF ONCOLOGY
- 1160P Efficacy and biomarker identification of neoadjuvant chemo-immunotherapy in potentially resectable non-small cell lung cancer
- (2021) Y. Zhang et al. ANNALS OF ONCOLOGY
- 1176P Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
- (2021) X. Zhu et al. ANNALS OF ONCOLOGY
- The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer.
- (2021) Yongchang Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
- (2021) Sacha I. Rothschild et al. JOURNAL OF CLINICAL ONCOLOGY
- AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
- (2021) Helen J. Ross et al. JOURNAL OF CLINICAL ONCOLOGY
- Statistics From A (Agreement) to Z (z Score): A Guide to Interpreting Common Measures of Association, Agreement, Diagnostic Accuracy, Effect Size, Heterogeneity, and Reliability in Medical Research
- (2021) Patrick Schober et al. ANESTHESIA AND ANALGESIA
- Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer
- (2021) Hongsheng Deng et al. ANNALS OF SURGERY
- P03.01 Pathologic Response to Neoadjuvant PD-1 Inhibitors and Chemotherapy in Squamous Non-Small-Cell Lung Cancer
- (2021) L. Shi et al. Journal of Thoracic Oncology
- OA11.01 Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer
- (2021) J. Bar et al. Journal of Thoracic Oncology
- Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
- (2021) Yan Hu et al. Frontiers in Oncology
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
- (2020) Ralph Zinner et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer.
- (2020) Christopher Lemmon et al. JOURNAL OF CLINICAL ONCOLOGY
- 1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis
- (2020) N.A. Waser et al. ANNALS OF ONCOLOGY
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
- (2020) Xiao-hui Jia et al. LUNG CANCER
- Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
- (2020) Arafat Tfayli et al. Cancer Medicine
- 62MO A randomised, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC
- (2020) J. Lei et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes
- (2019) Waqar Haque et al. LUNG CANCER
- Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer
- (2018) Chi-Fu Jeffrey Yang et al. ANNALS OF THORACIC SURGERY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiation Therapy Oncology Group Protocol 02-29: A Phase II Trial of Neoadjuvant Therapy With Concurrent Chemotherapy and Full-Dose Radiation Therapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-small Cell Carcinoma of the Lung
- (2012) Mohan Suntharalingam et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials
- (2012) Guillaume Mouillet et al. Journal of Thoracic Oncology
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More